For functional testing, we employed the TeloDIAG, a combined assay that integrates telomere content quantification [19] with CC detection [11], thereby providing a robust evaluation of the functional consequences of ATRX mutations for clinical glioma diagnosis. The gene discussed is ATRX; the disease is glioma.